RYAN DALY: Open Payments
NPI 1356124432 · LEWISTON, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,682 in 86 payments from 19 companies in 2025. Trend: 2023 $95 · 2024 $883 · 2025 $1,682
Food & beverage: $1,682
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $475 |
| ABBVIE INC. | 16 | $197 |
| PFIZER INC. | 15 | $188 |
| GlaxoSmithKline, LLC. | 17 | $168 |
| Lundbeck LLC | 6 | $104 |
| Teva Pharmaceuticals USA, Inc. | 2 | $68 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $65 |
| Neurocrine BioSciences, Inc. | 2 | $53 |
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
| Novo Nordisk Inc | 3 | $48 |
Products named: AIRSUPRA, BREZTRI, NURTEC ODT, REXULTI, TRELEGY ELLIPTA, QULIPTA, AUSTEDO XR, CAPLYTA.
Industry payments across ID — which companies pay providers there.
